Market news

Detailed price information for Palo Alto Networks (PANW-Q) from The Globe and Mail including charting and trades.

Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 5.8% in the afternoon session after genomics provider Sampled announced a five-year contract worth up to $27.1 million from the U.S. Department of Veterans Affairs to support research using PacBio Revio sequencing systems.

In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.62, marking a +2.53% move from the previous day.

Pacific Biosciences of California (NASDAQ:PACB) is maintaining its existing strategy while sharpening execution around clinical genomics, cost controls and the rollout of products designed to improve sequencing economics, Chief Executive Officer Mark Van Oene said during a Morgan Stanley discussion.

In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.38, indicating a +2.99% shift from the previous trading day.

Pacific Biosciences of California (PACB) closed at $1.27 in the latest trading session, marking a -1.55% move from the prior day.

Detailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at PacBio (NASDAQ:PACB) and the best and worst performers in the life sciences tools & services industry.

Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MENLO PARK, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 4:50 PM ET in New York, New York. A live webcast of the event can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcast will be ava

PacBio cut its 2026 revenue outlook as weaker instrument demand and a slower SPRQ-Nx transition raised the stakes for clinical adoption.

Pacific Biosciences of California (NASDAQ:PACB) reported second-quarter revenue of $39 million, including $20 million in consumables revenue, $13 million in instrument revenue and $6 million in services revenue, CFO Jim Gibson said during the Canaccord Genuity Growth Conference. Revenue increased s

PacBio’s second quarter was met with a negative market reaction, as sales and adjusted earnings per share both fell short of Wall Street’s expectations. Management attributed the underperformance to ongoing funding constraints in the U.S. academic and government sectors, as well as a transition period as customers validated the new SPRQ-Nx chemistry. CEO Mark Van Oene, newly appointed after Christian Henry’s departure, stated that “customer enthusiasm for SPRQ-Nx has remained strong since full l

Detailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.

Detailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.

Detailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0.00% and -4.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Genomics company Pacific Biosciences of California (NASDAQ:PACB) fell short of the market’s revenue expectations in Q2 CY2026, with sales falling 1.9% year on year to $39.01 million. Its non-GAAP loss of $0.14 per share was 10.4% below analysts’ consensus estimates.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Christian Henry to Transition from President and Chief Executive Officer Following Six Years of Leadership; Effective August 5, 2026MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions, today announced that its Board of Directors has appointed Mark Van Oene as President and Chief Executive Officer, effective August 5, 2026. Mr. Van Oene, who has served as

Moby summary of Pacific Biosciences of California, Inc.'s Q2 2026 earnings call

Detailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.

Pacific Biosciences of California (PACB) reached $1.39 at the closing of the latest trading day, reflecting a +2.21% change compared to its last close.

In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.36, indicating a -5.56% shift from the previous trading day.

Pacific Biosciences of California (PACB) concluded the recent trading session at $1.49, signifying a -4.49% move from its prior day's close.

Discover promising genetic sequencing stocks and stay ahead in the genomics revolution. Learn which companies are driving DNA technology forward.

Detailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.

PACB's growth is supported by HiFi sequencing advances and product momentum, though funding pressures weigh on instrument demand.

Pacific Biosciences of California (PACB) closed the most recent trading day at $1.66, moving 1.19% from the previous trading session.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) has gained more than 12% over the past month and roughly 35% since the global launch of SPRQ-Nx sequencing chemistry. Wall Street expects more than 59% upside from the current level, making it one of the Best Rising Penny Stocks to Buy According to Wall Street Analysts. Pacific Biosciences […]